Trial · NCT00536601
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Acute Leukemia | BuCy | 33 | 95% Confidence Interval 0 to 71 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Hodgkin Lymphoma | BuCy | 14 | 95% Confidence Interval 0 to 40 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Non-Hodgkin Lymphoma | BuCy | 22 | 95% Confidence Interval 7 to 38 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Hodgkin Lymphoma | CBV | 43 | 95% Confidence Interval 17 to 69 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Non-Hodgkin Lymphoma | CBV | 37 | 95% Confidence Interval 23 to 52 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Non-Hodgkin Lymphoma | VCp | 0 | 95% Confidence Interval 0 to 0 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Solid Tumors | VCp | 43 | 95% Confidence Interval 6 to 80 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | MM/Amyloid | Mel120 | 22 | 95% Confidence Interval 2 to 41 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | MM/Amyloid | Mel200 | 13 | 95% Confidence Interval 3 to 22 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Solid Tumors | CyTtCp | 0 | 95% Confidence Interval 0 to 0 | Proportion of participants |
| Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors) | Solid Tumors | TtC1500 | 50 | 95% Confidence Interval 0 to 100 | Proportion of participants |
| Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal)) | Acute Leukemia | 1 | Participants | ||
| Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal)) | Hodgkin Lymphoma | 9 | Participants | ||
| Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal)) | Non-Hodgkin Lymphoma | 19 | Participants | ||
| Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal)) | MM/Amyloid | 31 | Participants | ||
| Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal)) | Solid Tumors | 3 | Participants | ||
| Response Rate (Complete Remission) | Acute Leukemia | 5 | Participants | ||
| Response Rate (Complete Remission) | Hodgkin Lymphoma | 17 | Participants | ||
| Response Rate (Complete Remission) | Non-Hodgkin Lymphoma | 54 | Participants | ||
| Response Rate (Complete Remission) | MM/Amyloid | 17 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00536601/results